Results 71 to 80 of about 114,558 (301)

Daganatos sejtek rezisztenciáját gátló vegyületek fejlesztése = Development of compounds targeting multidrug resistant cancer [PDF]

open access: yes, 2009
A korszerű daganatellenes terápia jelentős sikerei ellenére a kemoterápiával szemben fellépő rezisztencia (multidrog rezisztencia, MDR) továbbra is megoldásra váró klinikai kihívás.
Szakács, Gergely
core  

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

open access: yes, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T   +14 more
core   +1 more source

ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Kaixin Yan   +9 more
wiley   +1 more source

Predicting human pharmacokinetics from preclinical data: absorption

open access: yesTranslational and Clinical Pharmacology, 2020
Predicting the rate and extent of oral absorption of drugs in humans has been a challenging task for new drug researchers. This tutorial reviews in vitro and PBPK methods reported in the past decades that are widely applied to predicting oral absorption in humans.
Dong-Seok Yim, Suein Choi, Soo Hyeon Bae
openaire   +2 more sources

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates [PDF]

open access: yesPharmaceutical Research, 2014
Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA approved ADCs on the market and over 30 ADCs in the clinical pipeline against a number of different cancer types. The structure of an ADC is very complex with multiple components
Kamath, Amrita V., Iyer, Suhasini
openaire   +2 more sources

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

open access: yesAdvanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Pharmacokinetics of Olivamide after Bolus Administration in Rats and Rabbits (a Pilot Study)

open access: yesАнтибиотики и Химиотерапия, 2020
The pharmacokinetics of olivamide, a semisynthetic antitumor derivate of olivomycin A, were studied in rats and rabbits after bolus administration. Plasma concentrations of olivamide were determined by an HPLC assay.
Yu. A. Portnoy   +6 more
doaj  

The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats

open access: yesFrontiers in Pharmacology, 2019
Introduction: Previous studies demonstrated that 35 mM QX-OH/10 mM Levobupivacaine (LL-1), a fixed-dose combination, produced a long-acting effect in rat local anesthesia models.
YuJun Zhang   +13 more
doaj   +1 more source

Ultrasmall Platinum Nanoparticles for Radiation‐Enhanced Cancer Therapy

open access: yesAdvanced Functional Materials, EarlyView.
This work proposes a nanomedicine‐based strategy to enhance X‐ray radiotherapy for cancer treatment. Ultrasmall Pt‐NPs exhibit catalase‐like activity that may contribute to modulation of the tumor microenvironment and amplify interactions between radiation and biological matter, leading to increased DNA damage.
Miguel Encinas‐Gimenez   +8 more
wiley   +1 more source

Approaches to Drug Pharmacokinetics Study Design in Preclinical Trials (Review)

open access: yesРегуляторные исследования и экспертиза лекарственных средств
INTRODUCTION. According to drug registration requirements, a registration dossier should include the data on preclinical trials of drug pharmacokinetics.
M. V. Karlina   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy